Theoretical and Natural Science

- The Open Access Proceedings Series for Conferences


Theoretical and Natural Science

Vol. 6, 03 August 2023


Open Access | Article

1-MHC as a target for cancer treatments

Qingxuan Gai 1 , Yibo Quan 2 , Hoi-Wa Tsang * 3 , Ziyang Wang 4
1 China Medical University
2 Basis International Park Lane Harbour
3 The Affiliated International School (YHV) of Shenzhen University
4 Walnut High School

* Author to whom correspondence should be addressed.

Theoretical and Natural Science, Vol. 6, 445-449
Published 03 August 2023. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Qingxuan Gai, Yibo Quan, Hoi-Wa Tsang, Ziyang Wang. 1-MHC as a target for cancer treatments. TNS (2023) Vol. 6: 445-449. DOI: 10.54254/2753-8818/6/20230295.

Abstract

Class-1 Major Histocompatibility Complex (MHC) molecules plays an important role in the immune system by exposing antigens to T cells for identification and destruction. Cancer cells often evade the immune system by downregulating MHC expression, avoiding detection from immune cells. Therefore, Class-1 MHC molecules are potential targets for cancer treatments. Recent studies have shown that increasing MHC expression in cancer cells can enhance T cell recognition and enhance the efficacy of immunotherapies, such as checkpoint inhibitors and adoptive cell transfer therapies. In addition, some therapeutic approaches are aimed at directly targeting Class-1 MHC molecules. This paper summarizes the mechanism of MHC expression, the current status of cancer treatments, relevant research status of class-1 MHC as a target in cancer therapy, and how this technique can be improved. These findings highlight the potential of Class-1 MHC as a promising target for cancer treatment, and further research is needed to fully exploit this target for the benefit of cancer patients.

Keywords

Class-1 MHC, immunotherapy, cancer

References

1. Ying guo Health 2022 Talking about the treatment of cancer | Cancer | Talking | Methods | Cancer cells | Treatment | Anticancer | Drugs <https://www.cn-healthcare.com/articlewm/20201209/content-1170626>.

2. Chemotherapy Side Effects | American Cancer Society <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html>

3. Radiotherapy | Cancer Treatment | Cancer Research UK <https://www.cancerresearchuk.org/about-cancer/treatment/radiotherapy>

4. Targeted Therapy for Cancer - NCI <https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies>

5. Fei D, Nianwei Q. A Brief Introduction to the Nobel Prizes Related to Immunology[J].Journal of Cellular and Molecular Immunology,2008,No.134(07):746-749.

6. Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 110(2):163-9(2003).

7. Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front Immunol.17;8:292(2017).

8. Lanier LL, Phillips JH. NK cell recognition of major histocompatibility complex class I molecules. Semin Immunol.7(2):75-82(1995).

9. Dhatchinamoorthy K, Colbert J D, Rock K L. Cancer immune evasion through loss of MHC class I antigen presentation[J]. Frontiers in immunology, 12: 636568(2021).

10. Haworth KB, Leddon JL, Chen CY, Horwitz EM, Mackall CL, Cripe TP. Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer.62(4):571-6(2015).

11. Cornel AM, Mimpen IL, Nierkens S. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers (Basel).2;12(7):1760(2020).

12. Xiao H, Long J, Baobao W, Qinfu W, Haige W, Shaohua D, Qian T,Nan J, Changzhen F,Xing J, Fengshan G.MHC.Molecular and Tumor Immunity and Therapeutic Research Progress [J]. Life Sciences,33(07):833-843(2021).

13. Wang, C., Xiong, C., Hsu, Y., Wang, X., & Chen, L. Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and -independent adoptive immunotherapies. Annals Of Blood, 5 (2020).

14. Lakna. Difference between MHC class 1 and 2: Definition, structure, antigen presentation, similarities and differences. Retrieved February 14(2023)

15. Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Frontiers in immunology, 12, 636568 (2021).

16. Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nature Reviews Immunology, 11(12), 823+ (2011).

17. Doordujin, E. M., Lora, A. M., Hall, T. V., Garrido, F., & Aptsiauri, N. The urgent need to recover MHC class I in cancers for effective immunotherapy.15 February 2023, < https://www.sciencedirect.com/science/article/pii/S0952791515001739>

18. Garrido, C., Paco, L., Romero, I., Berruguilla, E., Stefansky, J., Collado, A., Garcia-Lora, A. M. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells(2012).

19. Shklovskaya, E., & Rizos, H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. International Journal of Molecular Sciences, 22(13), 6741(2021).

20. Tau, G., & Rothman, P. Biologic functions of the IFN-gamma receptors. Allergy, 54(12), 1233–1251 (1999).

21. Seidel, J. A., Otsuka, A., & Kabashima, K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in oncology, 8, 86(2018).

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
ISBN (Print)
978-1-915371-65-2
ISBN (Online)
978-1-915371-66-9
Published Date
03 August 2023
Series
Theoretical and Natural Science
ISSN (Print)
2753-8818
ISSN (Online)
2753-8826
DOI
10.54254/2753-8818/6/20230295
Copyright
03 August 2023
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated